ICICI Direct has given Buy recommendation for Torrent Pharmaceuticals with a target price of Rs. 1730 in its research report issued on Sep 28, 2022
ICICI Direct’s research report on Torrent Pharmaceuticals
Incorporated in 1959, Torrent remains a key play in branded generics (~60% of sales) with a strong India franchise and growing exports traction. Revenues: India & CRAMs (57%), Brazil (9%), US (13%) and Germany (11%) • Torrent is the eighth largest domestic player and is ranked in top 10 for CVS, CNS, V&M, GI and anti-diabetes therapies in India.
Outlook
Valued at Rs 1730 i.e. 37x P/E on FY24E EPS of Rs 46.7.
More Info
At 16:01 hrs Torrent Pharmaceuticals was quoting at Rs 1,547.05, up Rs 52.15, or 3.49 percent.
It has touched an intraday high of Rs 1,554.00 and an intraday low of Rs 1,494.05.
It was trading with volumes of 13,710 shares, compared to its thirty day average of 13,862 shares, a decrease of -1.09 percent.
In the previous trading session, the share closed down 2.52 percent or Rs 38.70 at Rs 1,494.90.
The share touched its 52-week high Rs 1,652.23 and 52-week low Rs 1,242.50 on 31 December, 2021 and 12 May, 2022, respectively.
Currently, it is trading 6.37 percent below its 52-week high and 24.51 percent above its 52-week low.
Market capitalisation stands at Rs 52,359.20 crore.